Dissociation of bone formation markers in bone metastasis of prostate cancer
- PMID: 9184174
- PMCID: PMC2223543
- DOI: 10.1038/bjc.1997.273
Dissociation of bone formation markers in bone metastasis of prostate cancer
Abstract
To clarify the meaning and clinical value of bone formation markers in bone metastasis from prostate cancer, we investigated the bone formation markers carboxy-terminal propeptide of type I procollagen (PICP), bone-specific alkaline phosphatase (BA1-p) and osteocalcin, so-called bone gla protein (BGP) in 43 prostate cancer patients with and 46 patients without overt bone metastasis. Patients with bone metastasis were evaluated repeatedly by bone scan at intervals of 3-6 months. The expression patterns of bone formation markers in patients with progression of bone metastasis became dissociated; BA1-p and PICP were elevated in patients with progression of bone metastasis but BGP was not. Instead, BGP showed slight elevation in patients with improvement and complete remission of bone metastasis. PICP, BA1-p and BGP are all bone formation markers, but each marker appears in a different phase of bone formation: PICP appears in proliferation phase, BA1-p appears in matrix maturation phase and BGP appears in late bone formation phase. Our findings that BGP was not elevated in progression of bone metastasis and that it increased slightly with improvement and complete remission of bone metastasis may imply that the bone formation that occurs in blastic bone metastasis is different from normal bone formation.
Similar articles
-
Prognostic value of the serum levels of bone formation and bone resorption markers in prostate cancer patients with bone metastasis.Eur Urol. 1998 Aug;34(2):142-7. doi: 10.1159/000019700. Eur Urol. 1998. PMID: 9693250
-
Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.Jpn J Clin Oncol. 1996 Jun;26(3):157-63. doi: 10.1093/oxfordjournals.jjco.a023200. Jpn J Clin Oncol. 1996. PMID: 8656556
-
The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone.BJU Int. 2001 Mar;87(4):348-51. doi: 10.1046/j.1464-410x.2001.00105.x. BJU Int. 2001. PMID: 11251528
-
[Evaluation of cancer-induced bone diseases by bone metabolic marker].Clin Calcium. 2006 Apr;16(4):581- 90. Clin Calcium. 2006. PMID: 16582508 Review. Japanese.
-
[Bone scintigraphy for diagnosis of bone metastasis in patients with prostatic cancer].Nihon Rinsho. 2002 Dec;60 Suppl 11:135-9. Nihon Rinsho. 2002. PMID: 12599559 Review. Japanese. No abstract available.
Cited by
-
Markers of bone turnover for the management of patients with bone metastases from prostate cancer.Br J Cancer. 2000 Feb;82(4):858-64. doi: 10.1054/bjoc.1999.1012. Br J Cancer. 2000. PMID: 10732759 Free PMC article.
-
Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.Prostate. 2008 Jul 1;68(10):1116-25. doi: 10.1002/pros.20776. Prostate. 2008. PMID: 18461562 Free PMC article.
-
The Usefulness of Bone Biomarkers for Monitoring Treatment Disease: A Comparative Study in Osteolytic and Osteosclerotic Bone Metastasis Models.Transl Oncol. 2017 Apr;10(2):255-261. doi: 10.1016/j.tranon.2016.12.001. Epub 2017 Feb 16. Transl Oncol. 2017. PMID: 28214773 Free PMC article.
-
Three-dimensional trabecular bone architecture of the lumbar spine in bone metastasis from prostate cancer: comparison with degenerative sclerosis.Skeletal Radiol. 2005 Mar;34(3):149-55. doi: 10.1007/s00256-004-0855-x. Epub 2004 Nov 16. Skeletal Radiol. 2005. PMID: 15723255
-
Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer.Br J Cancer. 1997;76(6):760-4. doi: 10.1038/bjc.1997.458. Br J Cancer. 1997. PMID: 9310242 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous